166 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Masaryk University
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Nebraska Medical Center
RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Beni-Suef University
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Palack£
Synthesis and pharmacological evaluation of dehydroabietic acid thiourea derivatives containing bisphosphonate moiety as an inducer of apoptosis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Southeast University
Bis-isatin hydrazones with novel linkers: Synthesis and biological evaluation as cytotoxic agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Egyptian Russian University
Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Tours
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Icahn School of Medicine At Mount Sinai
Discovery of novel 5-fluoro-N(2),N(4)-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Medical Sciences and Peking Union Medical College
9- and 11-substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Technische Universit£T Braunschweig
Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Amgen
Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Siedlce University of Natural Sciences and Humanities
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Icahn School of Medicine At Mount Sinai
Discovery of a Novel Series of CHK1 Kinase Inhibitors with a Distinctive Hinge Binding Mode.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nerviano Medical Sciences
5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nerviano Medical Sciences
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ansaris
Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hanyang University
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Imperial College
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ariad Pharmaceuticals
In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca R&D Boston
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nerviano Medical Sciences
Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Palacky£? University and Institute of Experimental Botany Ascr
Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nycomed Pharma
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Cyclacel
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nerviano Medical Sciences
5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Institute of Science and Technology
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nerviano Medical Sciences
Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
East China University of Science & Technology
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of South Australia
Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Institute For Organic Syntheses (Vuos)
Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shanghaitech University
First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nankai University
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Beijing Normal University
Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Endotherm
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Egyptian Russian University
Potential of Cyclin-Dependent Kinase Inhibitors as Cancer Therapy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Therachem Research Medilab
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Edinburgh
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
The First Affiliated Hospital of Zhengzhou University
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Lebanese American University
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eli Lilly
Recent advances in the development of cyclin-dependent kinase 7 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Tianjin University of Science and Technology
Discovery of CDK5 Inhibitors through Structure-Guided Approach.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of South Australia
3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Palack£
A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of South Australia Cancer Research Institute
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Science & Technology (Ust)
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Florida
Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eppley Institute For Research In Cancer and Allied Diseases
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Egyptian Russian University
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Palack£
Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Medical Sciences and Peking Union Medical College
Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide (CA224), a nonplanar analogue of fascaplysin, inhibits Cdk4 and tubulin polymerization: evaluation of in vitro and in vivo anticancer activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
De Montfort University
Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shanghai Pharmaceuticals Holding
Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Changzhou University
Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Daiichi Sankyo
ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Palack£
A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Beijing Normal University
An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Kwazulu-Natal
Trisubstituted purine inhibitors of PDGFR? and their antileukemic activity in the human eosinophilic cell line EOL-1.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Palack£
Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shihezi University
2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Kaiserslautern
A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Gpc Biotech
Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Nerviano Medical Sciences
Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Amgen
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Hoffmann-La Roche
3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Nerviano Medical Sciences
4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Palacky University
Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Lawrence Berkeley National Laboratory
Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Chinese Academy of Sciences
Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Palacky University
Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Cyclacel
2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Cyclacel
Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Astrazeneca
Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Astrazeneca
Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Astrazeneca
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Astrazeneca
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Astrazeneca
Novel CDK inhibition profiles of structurally varied 1-aza-9-oxafluorenes.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Martin-Luther-University Halle-Wittenberg
Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Sugen
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Pharmacia Italia
Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Dupont Pharmaceuticals
Parallel synthesis of acylsemicarbazide libraries: preparation of potent cyclin dependent kinase (cdk) inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Dupont Pharmaceuticals
Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Eli Lilly
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Eli Lilly
Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Eli Lilly
Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Eli Lilly
Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Eli Lilly
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Avenida De La Industria
Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Eli Lilly
Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Pfizer
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Parke-Davis Pharmaceutical Research
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Bristol-Myers Squibb
Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Bristol-Myers Squibb
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Bristol-Myers Squibb
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Bristol-Myers Squibb
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Bristol-Myers Squibb
Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Bristol-Myers Squibb
Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Bristol-Myers Squibb Pharmaceutical Research Institute